Bradykinin inhibits high glucose- and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 2, 2012, Pages

  Blaes, Nelly ^a   Pécher, Christiane ^a   Mehrenberger, Marion ^a   Cellier, Eric ^a   Praddaude, Françoise ^a   Chevalier, Jacques ^b   Tack, Ivan ^a   Couture, Réjean ^c   Girolami, Jean Pierre ^a  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Akt; B2 kinin receptor knockout mice; Epithelial growth factor; Fibrosis; Intercellular adhesion molecule 1; Renin angiotensin system; Transforming growth factor

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; GROWTH FACTOR; ICATIBANT; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; RAMIPRIL; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; GLOMERULUS; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

EID: 84863908223     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00437.2011     Document Type: Article

References (55)

1. Allard J, Buléon M, Cellier E, Renaud I, Pecher C, Praddaude F, Conti M, Tack I, Girolami JP. ACE inhibitor reduces growth factor receptor expression and signaling but also proteinuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 293: F1083-F1092, 2007.
2. Alric C, Pecher C, Cellier E, Schanstra JP, Poirier B, Chevalier J, Bascands JL, Girolami JP. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int 62: 412-421, 2002.
3. Bascands JL, Pecher C, Rouaud S, Emond C, Tack JL, Bastie MJ, Burch R, Regoli D, Girolami JP. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am J Physiol Renal Fluid Electrolyte Physiol 264: F548-F556, 1993.
4. Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D, Bruneval P, Marre M, Alhenc-Gelas F, Bouby N. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 76: 395-403, 2009.
5. Bovenzi V, Savard M, Morin J, Cuerrier CM, Grandbois M, Gobeil F Jr. Bradykinin protects against microvascular endothelial cell death induced by pathological stimuli. J Cell Physiol 222: 168-176, 2010.
6. Brosius F. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endoc Met Disord 9: 245-254, 2008.
7. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T. Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503-2512, 2009.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
9. Buleon M, Allard J, Jaafar A, Praddaude F, Dickson Z, Ranera MT, Pecher C, Girolami JP, Tack I. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 294: F1249-F1256, 2008.
10. Cellier E, Mage M, Duchêne J, Pecher C, Couture R, Bascands JL, Girolami JP. Bradykinin reduces growth factor-induced glomerular ERK1/2 phosphorylation. Am J Physiol Renal Physiol 284: F282-F292, 2003.
11. Chao J, Li HJ, Yao YY, Shen B, Gao L, Bledsoe G, Chao L. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen activated protein kinase activity. Hypertension 49: 490-497, 2007.
12. Cheng CY, Tseng HC, Yang CM. Bradykinin-mediated cell proliferation depends on transactivation of EGF receptor in corneal fibroblast. J Cell Physiol 227: 1367-1381, 2012.
13. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16: 1711-1722, 2005.
14. Colie S, Pecher C, Girolami JP, Blaes N. Modulation by bradykinin and nitric oxide of angiotensin II-induced apoptosis in a vascular smooth muscle cell phenotype. Int Immunopharmacol 8: 231-236, 2008.
15. Duchene J, Schanstra JP, Pecher C, Pizard A, Susini C, Esteve JP, Bascands JL, Girolami JP. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin induced inhibition of cell proliferation. J Biol Chem 277: 40375-40383, 2002.
16. Emond C, Bascands JL, Rakotoarivony J, Praddaude F, Bompart G, Pecher C, Ader JL, Girolami JP. Glomerular B2-kinin-binding sites in two-kidney, one-clip hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 260: F626-F634, 1991.
17. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin receptor blockade on the response to angiotensin-convertingenzyme inhibitor in normotensive subjects. N Engl J Med 339: 1285-1292, 1998.
18. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen expression involve prostacyclin. Hypertension 32: 84-88, 1998.
19. Galina E, Ley K. Leucocytes recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 17: 368-377, 2006.
20. Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol 296: F306-F316, 2009.
21. Glick AD, Jacobson HR, Haralson MA. Mesangial deposition of type I collagen in human glomerulosclerosis. Hum Pathol 23: 1373-1379, 1992.
22. Graness A, Hanke S, Boehmer FD, Pressek P, Liebmann C. Proteintyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogenactivated protein kinase by bradykinin in A431 cells. Biochem J 5: 441-447, 2000.
23. Grewal JS, Luttrell LM, Raymond JR. G Protein-coupled receptors desensitize and down-regulate epidermal growth factor receptors in renal mesangial cells. J Biol Chem 276: 27335-27344, 2001.
24. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 290: F214-F222, 2006.
25. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F. Genetically increased angiotensin I-converting enzyme level and renal complications in diabetic mouse. Proc Natl Acad Sci USA 98: 13330-13334, 2001.
26. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kinase II). Studies with bradykinin and other natural peptides. J Biol Chem 268: 9496-9503, 1993.
27. Kakoki M, Smithies O. The kallikrein system in health and disease of the kidney. Kidney Int 75: 1019-1030, 2009.
28. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H, Grant R, Nossov SB, Kim HS, Jennette JC, Feldman EL, Smithies O. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci USA 107: 10190-10195, 2010.
29. Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the B2 receptor. Proc Natl Acad Sci USA 101: 13302-13305, 2004.
30. Kramarenko II, Bunni MA, Raymond JR, Garnosvskaya MN. Bradykinin B2 receptor interacts with integrin alpha5beta1 to transactivate epidermal growth factor receptor in kidney cells. Mol Pharmacol 78: 126-134, 2010.
31. Kwak SJ, Paeng J, Kim do H, Lee SH, Nam BY, Kang HY, Li JJ, Jung DS, Han SH, Ryu DR, Park JT, Chang TI, Yoo TH, Han DS, Kang SW. Local kallikrein-kinin system is involved in podocyte apoptosis under diabetic conditions. Apoptosis 16: 478-490, 2011.
32. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross talk in chronic kidney diseases; a new therapeutic approach. Nat Med 11: 867-874, 2005.
33. Lavaud S, Michel O, Sassy-Prigent C, Heudes D, Bazin R, Bariéty J, Chevalier J. Early influx of glomerular macrophages precedes glomerulosclerosis in the obese Zucker rat model. J Am Soc Nephrol 7: 2604-2615, 1996.
34. Lee FT, Cao Z, Forbes JM. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 15: 2139-2151, 2004.
35. Oeseburg H, Iusuf D, van der Harst P, van Gilst WH, Henning RH, Roks AJ. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension 53: 417-422, 2009.
36. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593, 2003.
37. Park CW, Kim JH, Lee JW, Kim YS, Ahn HJ, Shin YS, Kim SY, Choi EJ, Chang YS, Bang BK. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cell is PKC-NF-kB-dependent. Diabetologia 43: 1544-1553, 2000.
38. Pawluczyk IZ, Patel SR, Harris KP. The role of bradykinin in the antifibrotic actions of perindoprilat on mesangial cells. Kidney Int 65: 1240-1251, 2004.
39. Peten EP, Striker LJ, Carome MA, Elliott SJ, Yang CW, Striker GE. The contribution of increased collagen synthesis to human glomerulosclerosis: a quantitative analysis of alpha 2IV collagen mRNA expression by competitive polymerase chain reaction. J Exp Med 176: 1571-1576, 1992.
40. Runyan CE, Schnaper HW, Poncelet AC. The phosphatidylinositol 3-kinase/akt pathway enhances Smad3-stimulated mesangial cell collagen expression in response to transforming growth factor-beta1. J Biol Chem 279: 2632-2639, 2004.
41. Schanstra JP, Bataillé E, Marin Castaño ME, Barascud Y, Hirtz C, Pesquero JB, Pecher C, Gauthier F, Girolami JP, Bascands JL. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured lung fibroblats. J Clin Invest 101: 2080-2091, 1998.
42. Schanstra JP, Duchene J, Praddaude F, Bruneval P, Tack I, Chevalier J, Girolami JP, Bascands JL. Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284: H1904-H1908, 2003.
43. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa MA, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371-379, 2002.
44. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta-1 in renal fibrosis of rats. Hypertension 35: 1078-1084, 2000.
45. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACE inhibition to angiotensin I antagonists. Kidney Int 57: 1803-1817, 2000.
46. Tan Y, Keum JS, Wang B, McHenry MB, Lipsitz SR, Jaffa AA. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 293: F1026-F1035, 2007.
47. Tan Y, Wang B, Keum JS, Jaffa AA. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 288: F483-F492, 2005.
48. Tang SC, Chan LY, Leung JC, Cheng AS, Chan KW, Lan HY, Lai KN. Bradykinin and high glucose promote renal tubular inflammation. Nephrol Dial Transplant 25: 698-710, 2010.
49. Tschöpe C, Schultheiss HP, Walther T. Multiple interactions between the renin-angiotensin and kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 39: 478-487, 2002.
50. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, Higashiyama S, Iwasaka T. Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int 62: 799-808, 2002.
51. Uttarwar L, Peng D, Wu D, Kumar S, Gao B, Ingram J, Krepinsky JC. HB-EGF release mediates glucose induced activation of epidermal growth factor receptor in mesangial cells. Am J Physiol Renal Physiol 300: F921-F931, 2011.
52. Wu D, Peng F, Zhang B, Ingram AJ, Kelly DJ, Gilbert RE, Gao B, Kumar S, Krepinsky JC. EGFR-PLCγ signaling mediates high glucoseinduced PKCβ1-Akt activation and collagen 1 upregulation in mesangial cells. Am J Physiol Renal Physiol 297: F822-F834, 2009.
53. Wu D, Peng F, Zhang B, Ingram AJ, Kelly DJ, Gilbert RE, Gao B, Krepinsky JC. PKC-beta1 mediates glucose Akt activation and TGFbeta1 upregulation in mesangial cells. J Am Soc Nephrol 20: 554-566, 2009.
54. Wu J, Mei C, Vlassara H, Striker GE, Zheng F. Oxidative stressinduced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells. Am J Physiol Renal Physiol 297: F1622-F1631, 2009.
55. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 15, Suppl 1: S55-S57, 2004.